Equibles does not estimate personal net worth.
Get an email with a short summary when Rhythm Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RYTM alertsHunter Smith is recorded as CEO and CFO at Rhythm Pharmaceuticals, Inc. (RYTM). The newest filing on record that lists Hunter Smith as CFO at Rhythm Pharmaceuticals, Inc. (RYTM) is dated April 29, 2026. The newest filing on record that lists Hunter Smith as CEO at Rhythm Pharmaceuticals, Inc. (RYTM) is dated April 29, 2020. The proxy statement of Rhythm Pharmaceuticals, Inc. reports total compensation of $6,228,429 for Hunter Smith in fiscal 2025, including a base salary of $540,477. Disclosed compensation is on record for 8 fiscal years. Hunter Smith has spoken on 22 earnings calls and 2 other investor events across 1 company, most recently for Rhythm Pharmaceuticals, Inc. on November 11, 2026. Rhythm Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rhythm Pharmaceuticals, Inc. includes David P. Meeker, M.D. (CEO and Chairman), David Meeker (Chairman), Christophe R. Jean (Board Member) and 5 others.
“And first of all, thank you to Paul and the entire Steeple team for this conference, which is always a highlight of the year. It's a great location. There's always great swag.”
“Rhythm exit is the third quarter in a strong financial position and encouraged by the early U.S. launch execution required HO.”
“We exited the second quarter in a solid financial position and are encouraged by our strong initial launch execution and acquired HO in the U.S. At the same time, we continue to make meaningful progress with BBS in the U.S. and internationally, underscoring the strength of our business and the opportunity we see for…”
“So, first of all, let me thank you, Dennis, and the great team at Jeffries for hosting this conference. This is one of the highlights of the conference year, right to be here in the heart of Manhattan.”
“Rhythm is well capitalized and off to a strong start of what promises to be a transformational 2026. The initial phase of the U.S. launch and acquired HO is quite encouraging, and we're excited about the significant ongoing progress in the international region as well.”
Start not stated–present
Last confirmed April 29, 2020
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $540,477 | $6,228,429 |
| 2024 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $499,385 | $5,050,410 |
| 2023 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $476,154 | $2,308,007 |
| 2022 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $460,000 | $1,215,125 |
| 2021 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $435,957 | $2,309,413 |
| 2020 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $416,118 | $2,662,468 |
| 2019 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer | $393,992 | $1,922,853 |
| 2018 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Financial Officer, Treasurer, Secretary and Interim President and Chief Executive Officer | $387,600 | $1,587,137 |
